Inflammatory markers for risk stratification in primary prevention of cardiovascular disease: Time for a ‘multimarker’ approach?

Ignatios Ikonomidis; John Lekakis; Dimitrios T. Kremastinos

doi:10.1160/TH06-02-0073

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2006; 95(03): 397-398
DOI: 10.1160/TH06-02-0073

Editorial Focus

Schattauer GmbH

Inflammatory markers for risk stratification in primary prevention of cardiovascular disease: Time for a ‘multimarker’ approach?

Authors

Ignatios Ikonomidis

¹2nd Cardiology Department, Attikon Hospital, University of Athens, Athens, Greece
John Lekakis

¹2nd Cardiology Department, Attikon Hospital, University of Athens, Athens, Greece
Dimitrios T. Kremastinos

¹2nd Cardiology Department, Attikon Hospital, University of Athens, Athens, Greece

Abstract

Full Text

References

References
1 Ross R. Atherosclerosis – An inflammatory disease. N Engl J Med 1999; 340: 115-26.
2 Verma S. et al. C-reactive protein: structure affects function. Circulation 2004; 109: 1914-7.
3 Albert MA. et al. Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation 2003; 108: 161-5.
4 Ridker PM. et al. Plasma concentration of IL-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-72.
5 Pai JK. et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004; 351: 2599-610.
6 Cesari M. et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003; 108: 2317-22.
7 Tuomisto K. et al. C-reactive protein and tumor necrosis factor as predictors of incident coronary and cardiovascular events and total mortality. A population-based prospective study. Thromb Haemost 2006; 95: 511-8.
8 Ikonomidis I. et al. Increased circulating C-reactive protein and macrophage-colony stimulating factor are complementary predictors of long-term outcome in patients with chronic coronary artery disease. Eur Heart J 2005; 26: 1618-24.
9 Stollenwerk MM. et al. Very low density lipoprotein potentiates tumor necrosis factor-alpha expression in macrophages. Atherosclerosis 2005; 179: 247-54.
10 Bataille R, Klein B. C-reactive protein levels as a direct indicator of interleukin 6 levels in humans in vivo . Arthritis Rheum 1992; 35: 982-4.
11 Geng Y J. et al. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-γ, tumor necrosis factor-α, and interleukin-1β. Arterioscler Thromb Vasc Biol 1996; 16: 19-27.
12 Barath P. et al. Tumor necrosis factor gene expression in human vascular intimal smooth muscle cells detected by in situ hybridization. Am J Pathol 1990; 137: 503-9.
13 Reynolds GD, Vance RP. C-reactive protein immunohistochemical localisation in normal and atherosclerotic human aortas. Arch Pathol Lab Med 1987; 111: 265-9.
14 Kip KE. et al. Global inflammation predicts cardiovascular risk in women: a report from the Women’s Ischemia Syndrome Evaluation (WISE) study. Am HeartJ 2005; 150: 900-6.
15 Imhof A. et al. Effect of alcohol consumption on systemic markers of inflammation. Lancet 2001; 357: 763-7.
16 Singh U. et al. Vitamin E, oxidative stress, and inflammation. Annu Rev Nutr 2005; 25: 151-74.
17 Smith SC. et al. CDC/AHA Workshop on markers of inflammation and cardiovascular disease: Application to clinical and public health practice: report from the clinical practice discussion group. Circulation 2004; 110: 550-3.
18 Vlachopoulos C. et al. Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation 2005; 112: 2193-200.
19 Vasan RS. et al. Inflammatory markers and risk for heart failure in elderly subjects without prior myocardial infarction. The Framingham Heart Study. Circulation 2003; 107: 1486-91.
20 Ikonomidis I. et al. Myocardial ischemia induces interleukin 6 and tissue factor production in patients with coronary artery disease. A dobutamine stress echocardiography study. Circulation 2005; 112: 3272-9.